Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
Minerva Neurosciences (NASDAQ: NERV) will release its Q3 2021 financial results on November 8, 2021. A conference call is scheduled for 8:30 a.m. ET to discuss the results and business updates.
The company, focused on developing therapies for CNS disorders, is currently advancing its pipeline, including roluperidone for schizophrenia and MIN-301 for Parkinson's disease.
Investors can access the live call by dialing (877) 312-5845 (US) or (765) 507-2618 (international).
- Upcoming financial results release may signal progress in business development.
- Pipeline includes promising candidates for serious CNS disorders.
- None.
Management to Host Conference Call
WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the third quarter of 2021 on Monday, November 8, 2021. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 (US and Canada) or (765) 507-2618 (international) and referring to conference ID number 3775536. The live webcast of the conference call can also be accessed online in the Investors and Media section of the Company’s website under “Events and Presentations” at ir.minervaneurosciences.com.
The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 90 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Minerva’s portfolio of compounds includes roluperidone (MIN-101), in clinical development for negative symptoms of schizophrenia, and MIN-301, in pre-clinical development for Parkinson’s disease. For more information, please visit our website.
| For more information: | |
| Investor inquiries: | Media Inquiries: |
| Fred Ahlholm | Helen Shik |
| CFO, Minerva Neurosciences | Principal, Shik Communications LLC |
FAQ
When will Minerva Neurosciences release its Q3 2021 financial results?
What time is the Minerva conference call scheduled for?
How can I access the Minerva Neurosciences conference call?
What are the key products in Minerva's pipeline?
